JP2023155245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023155245A5 JP2023155245A5 JP2023125566A JP2023125566A JP2023155245A5 JP 2023155245 A5 JP2023155245 A5 JP 2023155245A5 JP 2023125566 A JP2023125566 A JP 2023125566A JP 2023125566 A JP2023125566 A JP 2023125566A JP 2023155245 A5 JP2023155245 A5 JP 2023155245A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- acid molecule
- vaccine
- separated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000000763 Survivin Human genes 0.000 claims 7
- 108010002687 Survivin Proteins 0.000 claims 7
- 229960005486 vaccine Drugs 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025056239A JP2025092647A (ja) | 2017-12-13 | 2025-03-28 | サバイビンを標的とするがんワクチンおよびその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598267P | 2017-12-13 | 2017-12-13 | |
| US62/598,267 | 2017-12-13 | ||
| JP2020532715A JP7385569B2 (ja) | 2017-12-13 | 2018-12-13 | サバイビンを標的とするがんワクチンおよびその使用 |
| PCT/US2018/065529 WO2019118766A2 (en) | 2017-12-13 | 2018-12-13 | Cancer vaccines targeting survivin and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532715A Division JP7385569B2 (ja) | 2017-12-13 | 2018-12-13 | サバイビンを標的とするがんワクチンおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025056239A Division JP2025092647A (ja) | 2017-12-13 | 2025-03-28 | サバイビンを標的とするがんワクチンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023155245A JP2023155245A (ja) | 2023-10-20 |
| JP2023155245A5 true JP2023155245A5 (enExample) | 2024-03-06 |
| JP7659599B2 JP7659599B2 (ja) | 2025-04-09 |
Family
ID=66734396
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532715A Active JP7385569B2 (ja) | 2017-12-13 | 2018-12-13 | サバイビンを標的とするがんワクチンおよびその使用 |
| JP2023125566A Active JP7659599B2 (ja) | 2017-12-13 | 2023-08-01 | サバイビンを標的とするがんワクチンおよびその使用 |
| JP2025056239A Pending JP2025092647A (ja) | 2017-12-13 | 2025-03-28 | サバイビンを標的とするがんワクチンおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532715A Active JP7385569B2 (ja) | 2017-12-13 | 2018-12-13 | サバイビンを標的とするがんワクチンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025056239A Pending JP2025092647A (ja) | 2017-12-13 | 2025-03-28 | サバイビンを標的とするがんワクチンおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12064473B2 (enExample) |
| EP (1) | EP3723793A4 (enExample) |
| JP (3) | JP7385569B2 (enExample) |
| KR (2) | KR20240038139A (enExample) |
| CN (1) | CN111479583A (enExample) |
| AU (2) | AU2018383664B2 (enExample) |
| BR (1) | BR112020011820A2 (enExample) |
| CA (1) | CA3083534A1 (enExample) |
| MX (2) | MX2020006285A (enExample) |
| RU (1) | RU2751253C1 (enExample) |
| WO (1) | WO2019118766A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240038139A (ko) * | 2017-12-13 | 2024-03-22 | 이노비오 파마수티컬즈, 인크. | 서바이빈을 표적으로 하는 암 백신 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028165A2 (en) | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| AU2013243952A1 (en) * | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| CN120514834A (zh) | 2014-03-28 | 2025-08-22 | 华盛顿大学商业中心 | 乳腺癌和卵巢癌疫苗 |
| JP6912384B2 (ja) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、ｒｎａ含有組成物 |
| EP3291842A4 (en) * | 2015-05-07 | 2019-01-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER |
| WO2017048850A1 (en) * | 2015-09-15 | 2017-03-23 | Advaxis, Inc. | Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment |
| KR20240038139A (ko) * | 2017-12-13 | 2024-03-22 | 이노비오 파마수티컬즈, 인크. | 서바이빈을 표적으로 하는 암 백신 및 이의 용도 |
-
2018
- 2018-12-13 KR KR1020247008261A patent/KR20240038139A/ko active Pending
- 2018-12-13 BR BR112020011820-6A patent/BR112020011820A2/pt unknown
- 2018-12-13 US US16/219,520 patent/US12064473B2/en active Active
- 2018-12-13 KR KR1020207019758A patent/KR102648079B1/ko active Active
- 2018-12-13 MX MX2020006285A patent/MX2020006285A/es unknown
- 2018-12-13 CN CN201880080439.6A patent/CN111479583A/zh active Pending
- 2018-12-13 JP JP2020532715A patent/JP7385569B2/ja active Active
- 2018-12-13 RU RU2020122872A patent/RU2751253C1/ru active
- 2018-12-13 CA CA3083534A patent/CA3083534A1/en active Pending
- 2018-12-13 EP EP18889469.5A patent/EP3723793A4/en active Pending
- 2018-12-13 WO PCT/US2018/065529 patent/WO2019118766A2/en not_active Ceased
- 2018-12-13 AU AU2018383664A patent/AU2018383664B2/en active Active
-
2020
- 2020-07-13 MX MX2025004799A patent/MX2025004799A/es unknown
-
2023
- 2023-08-01 JP JP2023125566A patent/JP7659599B2/ja active Active
-
2024
- 2024-07-08 US US18/765,553 patent/US20240358809A1/en active Pending
- 2024-11-18 AU AU2024264712A patent/AU2024264712A1/en active Pending
-
2025
- 2025-03-28 JP JP2025056239A patent/JP2025092647A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fukuyama et al. | Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques | |
| CN105944097B (zh) | 短肽作为疫苗佐剂的应用及疫苗 | |
| JP2008056679A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| JP2014519817A5 (enExample) | ||
| JP2023155245A5 (enExample) | ||
| JP2017522326A5 (enExample) | ||
| JP2020509770A5 (enExample) | ||
| JP2020502075A5 (enExample) | ||
| JP2005512518A5 (enExample) | ||
| WO2018037246A4 (en) | Immunogenic composition | |
| KR20230116700A (ko) | 단백질 발현을 위한 mRNA와 이를 위한 주형 | |
| EP3655025A2 (en) | Synthetic proteins and therapeutic uses thereof | |
| CN116603068A (zh) | 一种多肽疫苗递送载体及其制备方法 | |
| RU2011120447A (ru) | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины | |
| JP2020530453A5 (enExample) | ||
| JP2020533338A5 (enExample) | ||
| CN106459157A (zh) | 基于乙型肝炎核心抗原的疫苗 | |
| CN109415410B (zh) | 靶向树突细胞的肽、利用了该肽的肽融合体、及利用了该肽融合体的疫苗 | |
| JPWO2017096432A5 (enExample) | ||
| JP2011514167A5 (enExample) | ||
| BR112020023354A2 (pt) | vacina de peptídeo reverso | |
| Frassanito et al. | Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte | |
| RU2019113940A (ru) | Мозаичные вакцины от вируса ящура серотипа а | |
| CN107624117A (zh) | 基于乙型肝炎核心抗原的疫苗 |